Epidemiological and Metabolic Aspects and Risk Factors of Chronic Kidney Disease in Comorbid Pathology of Type 2 Diabetes Mellitus and Primary Hypothyroidism

Abstract

INTRODUCTION: The increasing number of patients with diabetes mellitus (DM) and chronic kidney disease (CKD) is one of the most pressing problems of modern medicine. In comorbid pathology — a combination of type 2 DM and thyroid hypofunction — the negative effect of hypothyroidism on carbohydrate metabolism, lipid metabolism, endothelial function, and glomerular filtration rate (GFR) is a risk factor for the formation and progression of diabetic nephropathy and CKD and requires further study.

AIM: To identify risk factors and epidemiological peculiarities of CKD in type 2 DM in combination with thyroid hypofunction and to determine the possibility of using cystatin C levels for the evaluation of the kidney function in this pathology.

MATERIALS AND METHODS: The prospective study involved 203 patients with type 2 DM undergoing inpatient treatment in the endocrinology department of the Ryazan Regional Clinical Hospital: group 1 (n = 76), type 2 DM combined with the primary hypothyroidism, and group 2 (n = 127), type 2 DM without thyroid pathology. Carbohydrate, lipid metabolism, albuminuria (AU), thyroid hormone spectrum, adipokines (leptin, plasminogen activator inhibitor-1, interleukin-6, and tumor necrosis factor-α) were analyzed. The GFR was calculated using the CKD-EPI formula based on the levels of creatinine and cystatin C. Arterial pressure daily monitoring (APDM) was conducted, and intra-abdominal fat thickness was evaluated by ultrasonography.

RESULTS: The incidence of kidney pathology in patients with type 2 DM was 52.22%. In group 1, there was a significant increase in the prevalence of CKD (64.47%, p = 0.006) and of normoalbuminuric CKD (NAU-CKD, 32.89%; p = 0.010). The risk of CKD development in patients with concomitant PH was more than twice that in patients without thyroid pathology with an odds ratio of 2.229 (95% confidence interval (CI) 1.241–4.003) and that for NAU-CKD was 2.474 (95% CI 1.267–4.833). Significant impairment of several metabolic parameters and individual APDM parameters was revealed in group 1 in comparison with group 2. The dependence of AU and GFR on the body mass index and of AU on the intra-abdominal fat thickness was noted. A negative relationship between GFR and leptin was revealed; in group 1, a correlation of interleukin-6 and thyrotropic hormone was found (r = 0.809, p = 0.001). With concomitant PH, cystatin C values were lower, and the GFR (CKD-EPI-cys) was reliably higher.

CONCLUSION: Hypothyroidism is a risk factor for CKD development including NAU-CKD in type 2 DM. Obesity and hormonal activities of the intra-abdominal fatty tissue facilitate AU progression and GFR reduction. The use of cystatin C as a marker of the filtration function of the kidney in patients with hypothyroidism may lead to the underestimation of kidney function; thus, further investigation is required.

Keywords

type 2 diabetes mellitus / primary hypothyroidism / chronic kidney disease / diabetic nephropathy / normoalbuminuric chronic kidney disease

References

[1] Shamkhalova MSh, Yarek-Martynova IR, Trubitcyna NP, et al. Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. Diabetes Mellitus. 2013;(3):97–102. (In Russ). doi: 10.14341/2072-0351-823

[2] Шамхалова М.Ш., Ярек–Мартынова И.Я., Трубицына Н.П., и др. Особенности сахароснижающей терапии у больных сахарным диабетом и хронической болезнью почек // Сахарный диабет. 2013. № 3. С. 97–102. doi: 10.14341/2072-0351-823

[3] Dedov II, M.V. Shestakova MV, editors. Oslozhneniya sakharnogo diabeta: lecheniye i profilaktika. Moscow: MIA; 2017. (In Russ).

[4] Дедов И.И., М.В. Шестакова М.В., ред. Осложнения сахарного диабета: лечение и профилактика. М.: МИА; 2017.

[5] Klimontov VV, Korbut AI. Normoalbuminuric chronic kidney disease in diabetes. Therapeutic Archive. 2018;90(10):94–8. (In Russ). doi: 10.26442/terarkh201890104-98

[6] Климонтов В.В., Корбут А.И. Нормоальбуминурическая хроническая болезнь почек при сахарном диабете // Терапевтический архив. 2018. Т. 90, № 10. C. 94–98. doi: 10.26442/terarkh201890104-98

[7] Afkarian M, Zelnick L, Hall Y, et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988–2014. JAMA. 2016;316(6):602–10. doi: 10.1001/jama.2016.10924

[8] Afkarian M., Zelnick L., Hall Y., et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988–2014 // JAMA. 2016. Vol. 316, № 6. Р. 602–610. doi: 10.1001/jama.2016.10924

[9] Porrini E, Ruggenenti P, Mogensen C, et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. The Lancet. Diabetes & Endocrinology. 2015;3(5):382–91. doi: 10.1016/S2213-8587(15)00094-7

[10] Porrini E., Ruggenenti P., Mogensen C., et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes // The Lancet. Diabetes & Endocrinology. 2015. Vol. 3, № 5. Р. 382–391. doi: 10.1016/S2213-8587(15)00094-7

[11] Marshall S.M. Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. Advances in Chronic Kidney Disease. 2014;21(3):267–72. doi: 10.1053/j.ackd.2014.03.007

[12] Marshall S.M. Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus // Advances in Chronic Kidney Disease. 2014. Vol. 21, № 3. Р. 267–272. doi: 10.1053/j.ackd.2014.03.007

[13] Orlova MM, Rodionova TI. Sostoyaniye funktsii pochek u patsiyentov s gipotireozom (obzor). Meditsinskiy Al’manakh. 2010;(3):112–4. (In Russ).

[14] Орлова М.М., Родионова Т.И. Состояние функции почек у пациентов с гипотиреозом (обзор) // Медицинский альманах. 2010. № 3 (12). С. 112–114.

[15] Connor А, Taylor JE. Renal impairment resulting from hypothyroidism. NDT Plus. 2008;1(6):440–1. doi: 10.1093/ndtplus/sfn158

[16] Connor А., Taylor J.E. Renal impairment resulting from hypothyroidism // NDT Plus. 2008. Vol. 1, № 6. P. 440–441. doi: 10.1093/ndtplus/sfn158

[17] Gilles R, der Hejier M, Ross AH, et. al. Thyroid function in patient with proteinuria. The Netherlands Journal of Medicine. 2008;66(11):483–5.

[18] Gilles R., den Hejier M., Ross A.H., et. al. Thyroid function in patient with proteinuria // The Netherlands Journal of Medicine. 2008. Vol. 66, № 11. P. 483–485.

[19] Furukawa S, Yamamoto S, Todo Y, et al. Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetes mellitus. Endocrine Journal. 2014;61(10):1011–8. doi: 10.1507/endocrj.ej14-0206

[20] Furukawa S., Yamamoto S., Todo Y., et al. Association between subclinical hypothyroidism and diabetic nephropathy in patients with type 2 diabetes mellitus // Endocrine Journal. 2014. Vol. 61, № 10. P. 1011–1018. doi: 10.1507/endocrj.ej14-0206

[21] Dubinina II, Uryasev OM, Berstneva SV, et al. Hypertension and endothelial dysfunction in comorbid pathology: diabetes mellitus and primary hypothyroidism. I.P. Pavlov Russian Medical Biological Herald. 2016;24(4):42–55. (In Russ). doi: 10.23888/PAVLOVJ2016442-55

[22] Дубинина И.И., Урясьев О.М., Берстнева С.В., и др. Артериальная гипертензия и дисфункция эндотелия при коморбидной патологии: сахарный диабет и первичный гипотиреоз // Российский медико- биологический вестник имени академика И.П. Павлова. 2016. Т. 24, № 4. С. 42–55. doi: 10.23888/PAVLOVJ2016442-55

[23] Berstneva SV. Epidemiological aspects of comorbid pathology — diabetes mellitus and hypothyroidism. Science of the young (Eruditio Juvenium). 2020;8(2):154–63. (In Russ). doi: 10.23888/HMJ202082154-163

[24] Берстнева С.В. Эпидемиологические аспекты коморбидной патологии — сахарный диабет и первичный гипотиреоз // Наука молодых (Eruditio Juvenium). 2020. Т. 8, № 2. С. 154–163. doi: 10.23888/HMJ202082154-163

[25] Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. European Journal of Endocrinology. 2009;160(5):785–90. doi: 10.1530/EJE-08-0797

[26] Maratou E., Hadjidakis D.J., Kollias A., et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism // European Journal of Endocrinology. 2009. Vol. 160, № 5. P. 785–790. doi: 10.1530/EJE-08-0797

[27] Zambon A, Bertocco S, Vitturi N, et al. Relevance of hepatic lipase to the metabolism of triacylglycerol rich lipoproteins. Biochemical Society Transactions. 2003;31(Pt 5):1070–4. doi: 10.1042/bst0311070

[28] Zambon A., Bertocco S., Vitturi N., et al. Relevance of hepatic lipase to the metabolism of triacylglycerol rich lipoproteins // Biochemical Society Transactions. 2003. Vol. 31, Pt. 5. P. 1070–1074. doi: 10.1042/bst0311070

[29] Deicher R, Hörl WH. Anaemia as a risk factor for the progression of chronic kidney disease. Current Opinion in Nephrology and Hypertension. 2003;12(2):139–43. doi: 10.1097/00041552-200303000-00003

[30] Deicher R., Hörl W.H. Anaemia as a risk factor for the progression of chronic kidney disease // Current Opinion in Nephrology and Hypertension. 2003. Vol. 12, № 2. P. 139–143. doi: 10.1097/00041552-200303000-00003

[31] Klimontov VV, Eremenko NV, Myakina NE, et al. Cystatin C and collagen type IV in diagnostics of chronic kidney disease in type 2 diabetic patients. Diabetes Mellitus. 2015;18(1):87–93. (In Russ). doi: 10.14341/DM2015187-93

[32] Климонтов В.В., Еременко Н.В., Мякина Н.Е., и др. Цистатин С и коллаген IV типа в диагностике хронической болезни почек у больных сахарным диабетом 2 типа // Сахарный диабет. 2015. Т. 18, № 1. Р. 87–93. doi: 10.14341/DM2015187-93

[33] Udovcic M, Pena RH, Patham B, et al. Hypothyroidism and the Heart. Methodist DeBakey Cardiovascular Journal. 2017;13(2):55–9. doi: 10.14797/mdcj-13-2-55

[34] Udovcic M., Pena R.H., Patham B., et al. Hypothyroidism and the Heart // Methodist DeBakey Cardiovascular Journal. 2017. Vol. 13, № 2. Р. 55–59. doi: 10.14797/mdcj-13-2-55

[35] Vyalkova AA, Lebedeva EN, Krasikov SI, et al. Clinical and paphogenical aspects of kidney damage in obesity (review). Nephrology. 2014;18(3):24–33. (In Russ).

[36] Вялкова А.А., Лебедева Е.Н., Красиков С.И., и др. Клинико-патогенетические аспекты повреждения почек при ожирении (обзор литературы) // Нефрология. 2014. Т. 18, № 3. С. 24–33.

[37] Zakharova SM, Savelieva LV, Fadeeva MI. Obesity and hypothyroidism. Obesity and Metabolism. 2013;(2):24–33. (In Russ).

[38] Захарова С.М., Савельева Л.В., Фадеева М.И. Ожирение и гипотиреоз // Ожирение и метаболизм. 2013. № 2. С. 54–58.

[39] Sazonova YeG, Mokhort TV. Thyroid functioning in diabetes mellitus complicated with chronic renal disease. Mezhdunarodnyy Endokrinologicheskiy Zhurnal. 2013;(2):62–7. (In Russ).

[40] Сазонова Е.Г., Мохорт Т.В. Тиреоидная функция при сахарном диабете, осложненном хронической болезнью почек // Международный эндокринологический журнал. 2013. № 2 (50). С. 62–67.

[41] Roos JF, Doust J, Tett SE, et al. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis. Clinical Biochemistry. 2007;40(5–6):383–91. doi: 10.1016/j.clinbiochem.2006.10.026

[42] Roos J.F., Doust J., Tett S.E., et al. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis // Clinical Biochemistry. 2007. Vol. 40, № 5–6. Р. 383–391. doi: 10.1016/j.clinbiochem.2006.10.026

[43] Čabarkapa V, Mijović R, Stošić Z, et al. Estimation of glomerular filtration rate from serum cystatin С and creatinine in patients with thyroid dysfunction. Journal of Medical Biochemistry. 2012;31(2):88–93. doi: 10.2478/v10011-011-0044-0

[44] Čabarkapa V., Mijović R., Stošić Z., et al. Estimation of glomerular filtration rate from serum cystatin С and creatinine in patients with thyroid dysfunction // Journal of Medical Biochemistry. 2012. Vol. 31, № 2. Р. 88–93. doi: 10.2478/v10011-011-0044-0

[45] Wiesli P, Schwegler B, Spinas GA, et al. Serum cystatin C is sensitive to small changes in thyroid function. Clinica Chimica Acta. 2003;338(1–2):87–90. doi: 10.1016/j.cccn.2003.07.022

[46] Wiesli P., Schwegler B., Spinas G.A., et al. Serum cystatin C is sensitive to small changes in thyroid function // Clinica Chimica Acta. 2003. Vol. 338, № 1–2. Р. 87–90. doi: 10.1016/j.cccn.2003.07.022

[47] Naour N, Fellahi S, Renucci J–F, et al. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity. 2009;17(12):2121–6. doi: 10.1038/oby.2009.96

[48] Naour N., Fellahi S., Renucci J.–F., et al. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity // Obesity. 2009. Vol. 17, № 12. P. 2121–2126. doi: 10.1038/oby.2009.96